Perrigo Reaches Agreement With Auditor Over Royalty Accounting

Ernst & Young demanded the Dublin drugmaker adjust its accounting for the multiple sclerosis drug Tysabri after Perrigo sold the royalty rights in a deal worth as much as $2.85 billion.

from WSJ.com: US Business http://ift.tt/2q507Q5
via IFTTT